Blockchain Registration Transaction Record

NeuroOne's OneRF System Gains Momentum with 50% of Ablations in Q1 2026

NeuroOne reports Q1 2026 results with 50% of OneRF ablations since launch occurring in the quarter. FDA-cleared trigeminal nerve system shows success in nine pain-free cases. Revenue projected to grow 17% to $10.5M.

This news matters because NeuroOne's technological advancements represent significant progress in treating debilitating neurological conditions that affect millions worldwide. The successful treatment of trigeminal neuralgia patients, with all nine cases reportedly pain-free, offers hope for those suffering from severe facial pain who have limited treatment options. The company's expansion into new markets for lower back pain, spinal cord stimulation, and drug delivery for brain tumors addresses critical unmet medical needs that impact quality of life and healthcare costs. As NeuroOne advances its FDA-cleared technologies and expands its intellectual property portfolio, it positions itself to transform neurological care by offering minimally invasive alternatives to pharmaceutical treatments and invasive surgeries, potentially reducing hospitalizations and improving patient outcomes across multiple conditions.